IMPACT BIOMEDICAL INC
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. EXECUTIVE COMPENSATION
No compensation has been paid to our executive officers or directors during the past two fiscal years.
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Stock Awards ($) | Option Awards ($) | All Other Compensation ($) | Total Compensation ($) |
|---|---|---|---|---|---|---|---|
| Frank D. Heuszel | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Chief Executive Officer, President and Director | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
| Mark Suseck | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Chief Operating Officer | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
| Todd D. Macko | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Chief Financial Officer | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
| Heng Fai Ambrose Chan | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Chairman of the Board | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dr. Elise Brownell | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Director | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
| Melissa Sims | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Director | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
| David Keene | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Director | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
| Christian Zimmerman | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Director | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
| Castel Hibbert | 2023 | $0 | $0 | $0 | $0 | $0 | $0 |
| Director | 2022 | $0 | $0 | $0 | $0 | $0 | $0 |
Employment Agreements
There are no employment agreements.
Director Compensation
The Company has not paid any compensation to any directors since inception.
Outstanding Equity Awards at Fiscal Year-End
There are no outstanding equity awards held by the Company’s named executive officers or directors as of December 31, 2023.
2023 Equity Incentive Plan
Our Board has adopted the 2023 Equity Incentive Plan, or 2023 Plan. As of December 31, 2023, no shares have been issued in relation to this plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.